Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLN logo SLN
Upturn stock ratingUpturn stock rating
SLN logo

Silence Therapeutics PLC (SLN)

Upturn stock ratingUpturn stock rating
$5.79
Last Close (24-hour delay)
Profit since last BUY40.88%
upturn advisory
Consider higher Upturn Star rating
BUY since 32 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: SLN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $32.37

1 Year Target Price $32.37

Analysts Price Target For last 52 week
$32.37Target price
Low$1.97
Current$5.79
high$22.46

Analysis of Past Performance

Type Stock
Historic Profit 169.39%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 273.46M USD
Price to earnings Ratio -
1Y Target Price 32.37
Price to earnings Ratio -
1Y Target Price 32.37
Volume (30-day avg) 7
Beta 1.41
52 Weeks Range 1.97 - 22.46
Updated Date 06/30/2025
52 Weeks Range 1.97 - 22.46
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.53

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -258.21%
Operating Margin (TTM) -18119.72%

Management Effectiveness

Return on Assets (TTM) -20.96%
Return on Equity (TTM) -53.13%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 90231360
Price to Sales(TTM) 9.87
Enterprise Value 90231360
Price to Sales(TTM) 9.87
Enterprise Value to Revenue 3.26
Enterprise Value to EBITDA -5.78
Shares Outstanding 47230300
Shares Floating 76035560
Shares Outstanding 47230300
Shares Floating 76035560
Percent Insiders 24.38
Percent Institutions 48.83

Analyst Ratings

Rating 3
Target Price 32.37
Buy 3
Strong Buy 3
Buy 3
Strong Buy 3
Hold -
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Silence Therapeutics PLC

stock logo

Company Overview

overview logo History and Background

Silence Therapeutics PLC was founded in 1994 and is a UK-based biotechnology company focused on the discovery and development of novel ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases with significant unmet medical needs. Initially focused on gene silencing technologies, it has evolved to focus on specific siRNA (small interfering RNA) therapies.

business area logo Core Business Areas

  • RNAi Therapeutics: The core business is the development of RNAi therapies, focusing on silencing specific genes to treat diseases. This includes the discovery, development, and clinical testing of siRNA candidates.
  • GalNAc Conjugates: Utilizes its proprietary mRNAi GOLDu2122 platform and GalNAc conjugation to deliver siRNA therapeutics to the liver and other tissues.

leadership logo Leadership and Structure

The leadership team includes the CEO, CFO, CSO, and other key executives. The organizational structure involves departments focused on research and development, clinical trials, regulatory affairs, and commercial strategy.

Top Products and Market Share

overview logo Key Offerings

  • SLN360: SLN360, targeting lipoprotein(a) (Lp(a)) for cardiovascular risk reduction. The market share of Lp(a) lowering therapies is emerging and difficult to quantify precisely, but significant. Competitors include Novartis (inclisiran) and Amgen, with their own Lp(a) targeting therapies in development.
  • SLN124: SLN124, an siRNA targeting TMPRSS6 for the treatment of anemia. There is currently no market share for this product as it is in clinical trials. The competitors include companies developing therapies for anemia associated with iron overload.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically within RNAi therapeutics, is rapidly evolving. This includes personalized medicine development and expanding targetable diseases.

Positioning

Silence Therapeutics PLC is positioned as a specialist in RNAi therapeutics. Their competitive advantage lies in their mRNAi GOLDu2122 platform technology and GalNAc delivery system, enabling targeted delivery of siRNA.

Total Addressable Market (TAM)

The total addressable market for RNAi therapeutics is estimated to be in the billions of dollars and is expected to grow significantly. Silence Therapeutics PLC is strategically positioned to capture a share of this market with its targeted therapies and proprietary technology.

Upturn SWOT Analysis

Strengths

  • Proprietary mRNAi GOLDu2122 platform technology
  • Targeted delivery systems
  • Strong pipeline of siRNA therapeutics
  • Experienced management team
  • Strategic partnerships with major pharmaceutical companies

Weaknesses

  • Reliance on clinical trial success
  • Limited number of approved products
  • Cash burn rate associated with R&D
  • Competition from larger pharmaceutical companies
  • Regulatory hurdles in drug development

Opportunities

  • Expanding pipeline with new siRNA targets
  • Partnerships with larger pharmaceutical companies for co-development and commercialization
  • Advancements in delivery technologies
  • Increasing acceptance and adoption of RNAi therapeutics
  • Positive clinical trial results to drive investor confidence

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other RNAi therapeutics companies
  • Intellectual property disputes
  • Economic downturn impacting investment in biotechnology

Competitors and Market Share

competitor logo Key Competitors

  • ALNY
  • REGN
  • ARWR
  • BNTX
  • MRNA

Competitive Landscape

Silence Therapeutics PLC's competitive advantages include its proprietary technology and GalNAc delivery system. Disadvantages include its smaller size and fewer approved products compared to larger pharmaceutical competitors.

Growth Trajectory and Initiatives

Historical Growth: Silence Therapeutics PLC has experienced growth in its pipeline of siRNA therapeutics and has strategic partnerships. Overall growth depends on the clinical trial successes and approval of its products.

Future Projections: Future growth projections are based on the success of its clinical trials and regulatory approvals. Analyst estimates vary, but the consensus view is that Silence Therapeutics PLC has significant growth potential if it brings its products to market.

Recent Initiatives: Recent initiatives include the advancement of its pipeline programs, new partnerships with pharmaceutical companies, and strategic R&D efforts.

Summary

Silence Therapeutics PLC is a biotechnology company focused on RNAi therapeutics and it has shown growth potential based on clinical trial outcomes and partnerships. The strengths of the company lie in its proprietary technology, but it needs to address the challenges related to regulatory approvals and competition. Silence Therapeutics needs to expand its market share within the RNAi therapeutics market. Silence Therapeutics PLC faces threats in the form of trial failures and regulatory setbacks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Estimates
  • Public news sources

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific events may impact actual performance.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Silence Therapeutics PLC

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-09-08
President, CEO & Executive Director Mr. Craig A. Tooman M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 116
Full time employees 116

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.